If Tonix doesn’t get FDA approval for their new fibromyalgia (FM) drug, it won’t be for lack of trying. The small drug manufacturer’s flagship product, TNX-102 SL, has had more ups and downs than a rollercoaster. It’s been pretty much given up...
Clinical Trials Ending This Year or Late Last Year The coronavirus pandemic stopped everything for quite a while but the clinical trials which survived the pandemic probably started up again quite some time ago. All we have to go by, though, are the stated completion...
Still at the Beginning? A recent review “Current and Emerging Pharmacotherapy for Fibromyalgia” examined the state of drug therapy for FM. It was a bluntly honest review. The news on the drug side has not been, after all, all that good in FM. A large study...
Both fibromyalgia (FM) and chronic fatigue syndrome (ME/CFS) clearly need better treatments. The FDA-approved drugs for these diseases are too often ineffective, come with too many side effects (fibromyalgia) or just aren’t available at all (ME/CFS). Too many...
Tomnya had everything going for it; a novel approach to pain and good Phase II trial results, but Tonix’s reformulation of Flexeril that was expected to help with both sleep and pain tanked in its critical Phase III trial. Check out what happened with it, and...
Subscribe
Subscribe To Health Rising’s Free Chronic Fatigue Syndrome, Fibromyalgia and Long COVID Information
